Czech Republic Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Czech Republic Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Czech Republic Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The Czech Republic will continue to be one of the most attractive markets in the CEE region for pharmaceutical and healthcare investment. A strong economic outlook will be the driving factor behind growt h and with plans to further increase access to healthcare , pharmaceutical sales are expected to increase over the coming years.

Headline Expenditure Projections

  • Pharmaceuticals: CZK78.83bn (USD3.02bn) in 2015 to CZK81.15bn (USD3.28bn) in 2016; +3.0 % in local currency terms and +8.7 % in US dollar terms. Forecasts in line with last quarter.

  • Healthcare: CZK312.52bn (USD11.97bn) in 2015 to CZK325.75bn (USD13.17bn) in 2016; +4.2% in local currency terms and +10.1% in US dollar terms. Forecasts revised upwards from last quarter .

Headline Pharmaceuticals & Healthcare Forecasts (Czech Republic 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: State Institute for Drug Control (SUKL), World Health Organisation, BMI
Pharmaceutical sales, USDbn 3.490 3.020 3.280 3.560 3.920 4.150 4.310
Pharmaceutical sales, % of GDP 1.80 1.76 1.77 1.76 1.73 1.70 1.68
Pharmaceutical sales, % of health expenditure 25.5 25.2 24.9 24.6 24.3 24.0 23.7
Health spending, USDbn 13.660 11.970 13.170 14.480 16.160 17.300 18.220

Risk/Reward Index

In Q3 2016, the Czech Republic Risk/Reward Index (RRI) score has been upgraded from the previous quarter to 65.5 out of 100. The Czech Republic is ranked as the most attractive market to innovative drugmakers in the Central and Eastern European (CEE) region within our RRI matrix. The Czech pharmaceutical market score is driven by high pharmaceutical expenditure per capita, an ageing population and a favourable urban-rural distribution, but dragged down by a challenging pricing and reimbursement environment.

Latest Updates

  • In April, representatives of the Ministries of Health for the Czech Republic, Hungary, Poland and Slovakia announced that they would consider cooperating in a joint purchasing agreement for rare disease medicines.

  • On April 6 2016, the Minister of Health announced a proposal to provide additional grants to doctors for medical equipment, nurses and salaries for practising in places where care is lacking. The new proposal is aimed at addressing the uneven distribution of healthcare provision around the country.

  • In March, the Czech Medical Council called on the government to introduce a health tax on alcohol and tobacco products.

BMI Economic View

Due partially to solid economic and employment growth rates, the Czech Republic's public finances will stay healthy in 2016 and 2017. Tax revenues will benefit from strong retail sales, while government borrowing costs will stay low amid record-low interest rates and the country's safe haven status.

BMI Political View

Relations between the Czech Republic and the EU will worsen over the coming quarters. We expect the Czech government to continue to oppose the EU's migrant reallocation system and re-introduce border controls in line with the other Central European states. Moreover, we believe further European integration will stay on hold in the years ahead.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Czech Republic 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2014-2020)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Czech Republic 2014-2020)
30
Industry Risk Reward Index
31
Central And Eastern Europe Risk/Reward Index - Q2 2016
31
Czech Republic - Risk/Reward Index
37
Rewards
37
Risks
37
Regulatory Review
38
Regulatory Regime
38
Pricing Regime
39
Reimbursement Regime
40
Table: European VAT Rates On Medicines (%)
43
Market Overview
46
Healthcare Sector
46
Table: Healthcare Resources (Czech Republic 2010-2015)
48
Table: Healthcare Personnel (Czech Republic 2010-2015)
48
Table: Healthcare Activity (Czech Republic 2010-2015)
49
Research & Development
52
Clinical Trials
53
Epidemiology
55
Competitive Landscape
58
Research-Based Industry
58
Table: Multinational Market Activity
58
Generic Drugmakers
59
Pharmaceutical Distribution
60
Pharmaceutical Retail Sector
60
Company Profile
62
Zentiva (Sanofi)
62
Demographic Data
66
Demographic Forecast
66
Table: Population Headline Indicators (Czech Republic 1990-2025)
67
Table: Key Population Ratios (Czech Republic 1990-2025)
67
Table: Urban/Rural Population & Life Expectancy (Czech Republic 1990-2025)
68
Table: Population By Age Group (Czech Republic 1990-2025)
68
Table: Population By Age Group % (Czech Republic 1990-2025)
69
Glossary
71
Methodology
73
Pharmaceutical Expenditure Forecast Model
73
Healthcare Expenditure Forecast Model
73
Notes On Methodology
74
Risk/Reward Index Methodology
75
Index Overview
76
Table: Pharmaceutical Risk/Reward Index Indicators
76
Indicator Weightings
77

The Czech Republic Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech Republic pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Czech Republic, to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.